CJC-1295 (No DAC) Research Peptide – Overview & Mechanism
MODIFIED GRF 1-29 | GHRH RECEPTOR RESEARCH
CJC-1295 (No DAC), also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). It is investigated for its interaction with GHRH receptors and associated pituitary signaling pathways.
Available in 5mg and 10mg lyophilized strengths, CJC-1295 No DAC is studied in the context of growth hormone (GH) regulation, cAMP signaling and the GH/IGF-1 endocrine axis. Unlike CJC-1295 with DAC, it lacks the albumin-binding modification associated with prolonged circulation.
Mechanism of Action
GHRH acts on receptors in anterior pituitary somatotroph cells, activating Gs proteins and adenylyl cyclase to increase intracellular cyclic AMP (cAMP). This signaling pathway contributes to growth hormone synthesis and secretion, with downstream effects involving IGF-1 regulation. Modified GRF 1-29 incorporates amino-acid substitutions within the active GHRH(1-29) sequence and is investigated in GHRH analogue and receptor research.
Key GHRH Research Pathways
Investigated for its role in hypothalamic-pituitary communication and growth hormone regulation.
GHRH receptor activation stimulates adenylyl cyclase and cAMP signaling in pituitary somatotroph cells.
Research examines growth hormone synthesis, secretion and interactions with other endocrine regulators.
The GH/IGF-1 axis is studied in endocrine and metabolic biology, including downstream responses to GH signaling.
CJC-1295 No DAC vs. CJC-1295 With DAC
Although frequently grouped together, these are chemically distinct compounds. The DAC-containing form includes an albumin-binding modification that changes its circulation profile.
| Characteristic | No DAC | With DAC |
|---|---|---|
| Common Name | Modified GRF 1-29 | CJC-1295 with DAC |
| Albumin-Binding DAC | Absent | Present |
| Circulation | Expected shorter persistence | Prolonged by albumin binding |
| Human Evidence | Limited direct published data | Early clinical studies available |
Human studies of DAC-containing CJC-1295 do not establish equivalent pharmacokinetic or endocrine effects for the No DAC form.
CJC-1295 No DAC for Research in Canada
Researched Peptides supplies CJC-1295 No DAC in 5mg and 10mg strengths for laboratory research in Canada. Independent HPLC-UV analytical documentation is available for a tested 5mg sample. Explore our CJC-1295 vs. Ipamorelin Research Analysis for additional scientific context.
For laboratory and scientific research purposes only. Not intended for human or veterinary use.


Delivered very fast – within 2 days after ordered. High quality product. Very satisfied customer and will continue to use their products.
fast shipping. products are good and clean. no bad reactions
Honestly the best and most amazing service ever! So helpful and extremely attentive. The shipping is quick as well! So far I’m loving my order. Thanks guys